WEAVER GREGORY L

CFO Weaver buys 10,000 ALT shares at $3.15; 30d down -25.0%, stock at 52w low range ($3.12 vs $7.71 high)

WEAVER GREGORY L, CFO of Altimmune, purchased 10,000 shares at $3.15 on 2026-04-01, increasing his holdings 35.6% from 28.1K to 38.1K shares. The transaction occurred amid significant stock weakness: the stock has declined -59.5% from its 52-week high of $7.71 to a current price of $3.12, with a particularly sharp -25.0% drop over the prior 30 days. The company's fundamentals present a mixed picture—revenue growth of 105.0% year-over-year is robust, but the company reported a net loss of $-19.0M on quarterly revenue of $5.0K, indicating an unprofitable operation with severe margin pressure. His prior buy at ALT on 2025-03-13 posted a 90-day return of +25.8%, and his cross-ticker track record shows a 100% 90-day win rate across 2 prior buys. However, the timing of this purchase—into a collapsing stock and an unprofitable business—warrants scrutiny of whether near-term fundamentals may remain challenged.

ALT CFO Gregory L Weaver buys 5,000 shares at $3.54 after 1-year 49.7% decline from $7.71 high

Gregory L Weaver, CFO of Altimmune, Inc., purchased 5,000 shares at $3.54 on 2026-03-06, increasing his holdings by 21.7% to 28,078 shares total. The buy occurs at a significant discount to the 52-week high of $7.71, with the stock currently -49.7% from that peak and -20.3% over the past 30 days. Weaver's prior buy at ALT on 2025-03-13 demonstrated positive 90-day performance (+25.8%), representing 1 of 1 well-timed buys in his open-market history at this ticker. However, context matters: the company reported revenue of $5,000.00 in its latest quarter against net losses of $-19,000,000.00 (full-year unprofitable), though annual revenue growth reached +105.0% year-over-year. The timing and magnitude of this accumulation merit scrutiny against the company's unprofitable state and recent price deterioration.

CFO Gregory Weaver buys 10,000 shares of ALT at $5.20; stock down 45.7% from 52-week high, company posted -95.3% annual revenue decline and -$22.8M net loss.

CFO Gregory Weaver purchased 10,000 shares at $5.20 on 2025-03-13, establishing an initial position of 10,000 shares. The purchase occurs at a price 45.7% below the 52-week high of $10.91, amid severe operational deterioration: annual revenue contracted 95.3% year-over-year and the company reported a net loss of -$22.8M on quarterly revenue of $5.0K. The stock has declined 34.4% over the past 90 days and 4.8% over 30 days. A CFO insider buy near 52-week lows in a company facing substantial revenue collapse and negative earnings warrants scrutiny regarding the rationale for this acquisition and whether management has visibility into stabilization or turnaround prospects not yet reflected in current market pricing.